Study reports two-year outcomes of diabetic macular edema treatment

A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that was previously demonstrated at 12 months was maintained through 24 months, according to a report published Online First by Archives of Ophthalmology.

Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular (MLT) has been the mainstay of treatment for clinically significant diabetic macular edema (CSME) for the . The procedure reduces the risk of moderate visual loss but visual acuity improves (a 15-letter gain at three years) in less than 3 percent of patients so better treatments have been sought, the authors write in their study background.

Ranjan Rajendram, M.D., F.R.C.Ophth., of Moorfields Eye Hospital, London, and colleagues report on the two-year outcomes of the BOLT study, a prospective of 80 patients that evaluated intravitreous (injections into the eye) and modified ETDRS MLT in patients with CSME.

At two years, the mean (average) ETDRS best-corrected visual acuity was 64.4 (Snellen visual acuity equivalent: 20/50) in the bevacizumab group and 54.8 (Snellen equivalent 20/80) in the MLT group, a mean gain of 8.6 letters for bevacizumab and a mean loss of 0.5 letters for MLT. The bevacizumab group gained a median of nine ETDRS letters versus 2.5 ETDRS letters for MLT at 24 months compared with baseline. At 24 months, 49 percent of patients gained 10 or more ETDRS letters and 32 percent gained 15 or more letters in the bevacizumab group compared with 7 percent and 4 percent in the MLT group.

"In conclusion, this investigator-initiated single-center study provides evidence for the longer-term use of bevacizumab in the treatment of persistent DME [diabetic macular edema]," the authors note " benefit was maintained through two years with a reduced injection frequency in the second year despite the long duration of DME and multiple MLTs before entering the study. This finding will be reassuring to physicians charged with delivery of this relatively new treatment."

More information: Arch Ophthalmol. Published online April 9, 2012. doi:10.1001/archophthalmol.2012.393

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Hygiene practices affect contact lens case contamination

Jan 28, 2015

Contact lens wearers who don't follow certain hygiene habits have increased bacterial contamination of their contact lens cases, reports a study in the February issue of Optometry and Vision Science, official journal of the ...

Team creates device to alleviate dry eye

Jan 26, 2015

A search for medical needs in eye clinics led Stanford Biodesign fellows to develop an implantable neurostimulator that painlessly increases natural tear production.

Scientists discover gene tied to profound vision loss

Jan 16, 2015

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.